Key Publications
-
Loh, A.H.P., Thura M., Gupta, A., Tan, S.H., Kuan, K. K. Y., Ang, K.W., Merchant, K., Chang, K.T.E., Yon, H.Y., Chen, Y., Cheng, M. H.W., Mahadev, A., Ng, M.C.H., Seng, M.S-F., Lyer,P., Chia, P.L., Soh, S.Y., and Zeng,Q., (2023) Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody. Molecular Therapy Oncolytics 30 (153-166)
-
Chee, C.E., Ooi. M., Lee, SC., Sundar, R., Heong, V., Yong, WP., Ng, C.H., Wong, A., Lim, J.S.J., Tan, D. S. P., Soo, R., Tan, J.T.C., Yang, S., Thura, M., Al-Aidaroos, A. Q., Chng, W. J., Zeng, Q., Boon-Cher Goh, BC. (2023) A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 18(2)
-
Chia, P.L., Ang, K. H., Thura, M., and Zeng, Q. (2023) PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics 13(6)
-
Thura, M., Sng, J. X. E., Ang, K. W., Li, J., Gupta, A., Hong, J. M., Hong, C. W., Zeng, Q. (2021) Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Biosci Rep 43 (9):BSR20211491
Our innovative antibody drugs provide new hope to
hard-to-treat cancer patients.
CONTACT US
Top
